Human urinary active kallikrein and prokallikrein were separated on DEAE-cellulose and octyl-Sepharose columns and both purified to homogeneity by affinity chromatography, gel filtration and hydrophobic h.p.l.c. Prokallikrein was monitored during purification by trypsin activation followed by determination of both amidase and kininogenase activity. After trypsin activation, purified prokallikrein had a specific kininogenase activity of 39.4 ,ug of bradykinin equivalent/min per mg and amidase activity of 16.5,umol/min per mg with D-Val-Leu-Arg-7-amino-4-trifluoromethylcoumarin. Purified active kallikrein had a specific activity of 47 ,ug of bradykinin/min per mg. The molecular mass of prokallikrein was 48 kDa on electrophoresis and 53 kDa on gel filtration whereas active kallikrein gave values of 46 kDa and 53 kDa respectively. Antisera to active and prokallikrein were obtained. In double immunodiffusion and immunoelectrophoresis, antiserum to active kallikrein reacted with active and pro-kallikrein. Antiserum to prokallikrein contained antibodies to determinants not found in active kallikrein, presumably due to the presence of the activation peptide in the proenzyme. Human prokallikrein can be activated by thermolysin, trypsin and human plasma kallikrein. Activation of50% ofthe prokallikrein (1.35 JtM) was achieved in 30 minwith 25 nM-thermolysin, 78 nM-trypsin or 180 nM-human plasma kallikrein. Thus thermolysin was the most effective activator. Thermolysin activated prokallikrein by releasing active kallikrein with N-terminal Ile1-Val2. Thus human tissue (glandular) prokallikrein can be activated by two types of enzymes: serine proteinases, which cleave at the C-terminus of basic amino acids, and by a metalloproteinase that cleaves at the N-terminus of hydrophobic amino acids.
INTRODUCTION
The existence of a precursor of glandular or tissue kallikrein (EC 3.4.21.35 ) that is activated by trypsin has been noted in tissues such as pancreas (Werle & Urhahn, 1940) , colon (Werle, 1960; Seki et al., 1972) , kidney (Nishimura & Erd6s, 1980; Nishimura et al., 1980a,b) or urine (Werle & Vogel, 1961) . As kallikrein is easily inhibited by various proteins and peptides (Kraut et al., 1930; Vogel, 1979) , it was unknown initially whether an enhancement in kallikrein activity was due to the activation of a proenzyme or to the removal of an inhibitor. The properties of the human urinary prokallikrein and its mode of activation have not been characterized. Corthorn et al. (1979) partially purified a human urinary prokallikrein by monitoring its esterase activity. Spragg (1983) also reported briefly the purification of human prokallikrein, but without details. Silver et al. (1980) developed an r.i.a. for active urinary kallikrein, and Oza et al. (1981) assayed both prokallikrein and kallikrein in a single r.i.a. According to these authors, about one-half to two-thirds of the potential kallikrein activity in human urine can be attributed to the inactive, latent, kallikrein. Because we consider the enzymicactivation step of prokallikrein to be crucial for the understanding of the multiple functions of this enzyme in kidney and elsewhere (Margolius, 1980 (Margolius, , 1984 Nasjletti & Malik, 1981) , we continued our studies on the conversion of renal and urinary prokallikrein into the active form (Nishimura et al., 1980a,b; Nishimura & Erdos, 1980; Yamada & Erd6s, 1982; Noda et al., 1985) . As described in this paper, we used human urine as a source of glandular (renal) kallikrein. We purified human urinary prokallikrein and active kallikrein to homogeneity from this source. We found that prokallikrein can be activated by enzymes that cleave either at the C-terminus of basic amino acids or at the N-terminus of hydrophobic amino acids to remove the activation propeptide sequence. In our experiments, the metalloproteinase thermolysin (EC 3.4.24.4) was the most efficient activator of prokallikrein, followed by trypsin (EC 3.4.21.4) and plasma kallikrein (EC 3.4.21.34) 
EXPERIMENTAL

Materials
Thermolysin was purchased from Calbiochem-Behring Corp. La Jolla, CA, U.S.A. D-Val-Leu-Arg-F3NMec and glutaryl-Ala-Ala-Phe-OMe-Nap were from Enzyme Systems Products, Livermore, CA, U.S.A. Trypsin was from bovine pancreas (type III, 12400 Bz-Arg-OEt units/mg), SBTI and dansyl chloride were from Sigma Chemical Co., Vol. 232 Abbreviations used: r.i.a., radioimmunoassay; F,NMec, 7-amino-4-trifluoromethylcoumarin; OMe-Nap, 4-methoxy-2-naphthylamine; BzArg-OEt, benzoylarginine ethyl ester; dansyl or Dns, 5-dimethylaminonaphthalene-1-sulphonyl; SBTI (Noda et al., 1985; Morita et al., 1977) and by r.i.a. of bradykinin released from dog kininogen (Noda et al., 1985) . Amidase activity with D-Val-Leu-ArgF3NMec is expressed as nmol ofsubstrate hydrolysed/min (1 nmol/min = I munit). The fluorescence generated was measured in an Aminco-Bowman spectrofluorometer at 400 nm excitation and 505 nm emission wavelength. Kininogenase activity was determined by r.i.a. and is expressed as bradykinin equivalents released/min (Noda et al., 1985) . Prokallikrein was routinely detected by activation with trypsin. Briefly, a 10-50 1ul sample was incubated with 2.5 sg of trypsin in 0.1 M-Tris/HCl buffer, pH 8.0 (final volume 500 pA), for 30 minat 37 'C. After the reaction was stopped by the addition of 10 c1 of SBTI (5 mg/ml), portions were assayed for kallikrein activity.
Purification of human urinary prokallikrein and active kallikrein. Human urine (101.5 litres) was collected from healthy volunteers into chilled bottles at 4 'C. A mixture of benzamidine, EDTA and NaN3 in 0.1 M-Tris/HCl buffer (pH 8.0) was added periodically to yield final concentrations of 1 mm, 2 mm and 0.02 % respectively. All subsequent procedures were carried out at 4 'C unless otherwise stated. Urine was filtered through filter paper (Whatman no. 1) and concentrated to 150 ml in an Amicon DC-2 hollow-fibre concentrator equipped with an H lP0 cartridge and in an Amicon ultrafiltration apparatus with a YM-10 membrane. The Tamm-Horsfall glycoprotein was then precipitated by adding NaCl to a concentration of 0.58 M (Corthorn et al., 1979) and removed by centrifugation at 3000 g for 30 min. The supernatant solution was dialysed against 0.05 M-Tris/ HCI buffer, pH 7.2, and then applied to a column (5 cm x 25 cm) ofAffi-Gel Blue that had been equilibrated with the same buffer. The pass-through fractions were collected (1450 ml) and concentrated to 137 ml. The concentrate was dialysed overnight against 20 mmsodium phosphate buffer, pH 6.0, and then applied to a DEAE-cellulose (DE 52) column (2.6 cm x 50 cm) equilibrated with the dialysis buffer. After washing with 1 litre of the same buffer, the column was developed with a linear gradient of NaCl (0-0.5 M) in 20 mM-sodium phosphate buffer, pH 6.0. This technique separated prokallikrein and active kallikrein, which were eluted with 0.18 and 0.24 M-NaCl respectively.
Octyl-Sepharose CL-4B was packed into a column (2.6 cm x 27 cm) and equilibrated with 10 mM-sodium phosphate buffer, pH 6.8, containing 1 M-(NH4)2S04. The partially purified prokallikrein was first dialysed against the same buffer, then centrifuged at 8000g for 20 min and the supernatant added to the column. After washing the column with 600 ml of the equilibration buffer, the protein was eluted with a decreasing gradient of (NH4)2SO4 consisting of 150 ml of 1 M-(NH4)2SO4 in 10 mM-sodium phosphate buffer, pH 6.8, and 300 ml of buffer. The tightly bound proteins were eluted with 50% (v/v) ethylene glycol in 10 mM-sodium phosphate buffer, pH 6.8. Active kallikrein, which was not completely removed on the DEAE-cellulose column, appeared in the pass-through fractions. Three prokallikrein peaks were observed: at conductivities of 36 and 21 mS [corresponding to 0.44 and 0.23 M-(NH4)2S04 respectively], and after elution with 50% ethylene glycol (Fig. 1 below) . The prokallikrein fractions containing most of the activity (fractions 140-170, Fig. 1 ) were pooled and concentrated.
The concentrate (15 ml) was dialysed overnight against 50 mM-imidazole/HCl buffer, pH 7.0, and then applied to a column of p-aminobenzamidine-Sepharose (1.2 cm x 20 cm) equilibrated with the same buffer. After washing the column with the starting buffer, it was developed with a linear gradient of guanidinium chloride (0-0.35 M) in 50 mM-imidazole/HCI buffer, pH 7.0. Prokallikrein was eluted with 0.15 M-guanidine. Active kallikrein, which was generated during this step of purification, was eluted later with 0.25 M-guanidine. Fractions containing prokallikrein were pooled and concentrated to 3 ml by ultrafiltration, and then applied directly to a Sephacryl S-200 column (2.6 cm x 90 cm) equilibrated with 10 mM-sodium phosphate buffer, pH 7.2, containing 0.1 M-NaCl and 0.02% NaN3. Fractions (3.3 ml each) were collected at a flow rate of 20 ml/h. Prokallikrein appeared in a single peak.
The final step in purification was carried out in a Waters gradient h.p.l.c. system (Skidgel et al., 1984) on a TSK Phenyl-SPW column. The column was equilibrated with 0.1 M-Tris/HCl buffer, pH 7.4, containing 1.7 M-(NH4)2SO4. Solid (NH4)2SO4 was added to the concentrate from the Sephacryl S-200 column to a final concentration of 1.7 M, and a 400 1ul portion (490,g of protein) was injected. The proteins were eluted with a linear gradient of(NH4)2S04 decreasing from 1.7 M to 0 M in 0.1 M-Tris/HCl buffer, pH 7.4, over 30 min at a flow rate of 1 ml/min. At 280 nm, two peaks of protein were detected: a minor peak eluted at 23.0 min and the major protein peak, containing prokallikrein, at 28.6 min.
Several injections were made and the peak eluted at 28.6 min was collected, concentrated to 1.7 ml and stored at -70°C.
The active kallikrein, separated from prokallikrein on the DEAE-cellulose column, was further purified by p-aminobenzamidine affinity chromatography, gel filtration on Sephacryl S-200 and reverse-phase h.p.l.c. on a TSK Phenyl-SPW column under the same conditions as those described above. This preparation released 47,ug of bradykinin equivalent/min per mg and in SDS/poly-acrylamide-gel electrophoresis gave a single band corresponding to a molecular mass of 46 kDa.
Preparation of thermolysin-and trypsin-Sepharose 4B. Thermolysin (71 mg, containing 50 mg of enzyme protein) and trypsin (50 mg) were covalently bound to 5 g of CNBr-activated Sepharose 4B according to the manufacturer's recommendations. Over 97% of each enzyme was coupled to Sepharose. The activities of thermolysin-Sepharose and trypsin-Sepharose were measured with glutaryl-Ala-Ala-Phe-OMe-Nap or DVal-Leu-Arg-F3NMeC substrates respectively. A 50,tl portion of each sedimented gel was incubated with the corresponding substrate (0.1 mM) in 500 #1 of 0.1 M-Tris/ HC1 buffer, pH 8.0, containing 10 mM-CaCl2 for 30 min on a turntable at room temperature. After centrifugation at 12000 g for 1 min, the fluorescence generated in the supernatant was measured in an Aminco-Bowman spectrofluorimeter at 340 nm excitation and 425 nm emission wavelength with glutaryl-Ala-Ala-Phe-OMeNap as substrate. With trypsin and the F3NMec substrate the two wavelengths were 400 and 505 nm. The activity of 50,1 (sedimented gel) of thermolysin-Sepharose was equivalent to 1.2 ,ug of free thermolysin, and that of 501, of trypsin-Sepharose equivalent to 5 #tsg of free trypsin.
Activation of purified prokallikrein. Purified prokallikrein (6.5 ,g; 1.35 ZM) was incubated with various concentrations of thermolysin (5-93 nM) trypsin (11-215 nM) homogeneous human plasma kallikrein (11-556 nM) or human urinary kallikrein (I1-109 nM) in 100,1u of 0.1 M-Tris HCI buffer, pH 8.0, for 30 and 60 min at 37 'C. The reaction was stopped by adding a mixture of phosphoramidon (1 /LM final concn) and SBTI (10 #g) to inhibit completely thermolysin, trypsin or plasma kallikrein. In control studies the inhibitors were added before prokallikrein and they completely inhibited the activation. A 20 ,ul portion of each sample was assayed for kininogenase activity by r.i.a. To determine the presence of traces of active kallikrein in the purified prokallikrein sample, an equal volume of the buffer was added to a 10-fold-concentrated sample (65 ,tg) and assayed as described above. In an additional experiment, purified prokallikrein (2 ,ug) was incubated with 100 ,tl of sedimented gel of thermolysin-or trypsin-Sepharose in 500 S1 of 0.1 M-Tris/HCl buffer, pH 8.0, containing 10 mM-CaCl2 for 10-240 min at room temperature. After centrifugation at 12000 g for 1 min, the activity in the supernatant was measured with D-Val-Leu-Arg-F3NMeC as substrate.
Molecular-mass determination. The molecular mass of active and pro-kallikrein were estimated by gel filtration on a column of Sephadex G-100 (1.6 cm x 92 cm) equilibrated with 10 mM-sodium phosphate buffer, pH 7.2, containing 0.1 M-NaCl and calibrated with molecular-mass markers. The flow rate was maintained at 10 ml/h, and 2 ml fractions were collected. Kallikrein activity was measured with D-Val-Leu-Arg-F3NMeC in each fraction before and after activation with trypsin or thermolysin (5,g/ml). For the determination of the molecular mass of thermolysin-and trypsin-activated kallikrein, purified prokallikrein (1 ml; 2 ,ug) was incubated with 100 ,l ofthermolysin-or trypsin-Sepharose for 1 h at room temperature. After centrifugation at 12000 g for 2 min, the supernatant (1 ml) was applied to the column. SDS/polyacrylamide-gel electrophoresis. SDS/polyacrylamide-gel electrophoresis was performed in 9% and 12% (w/v) slab gels at pH 8.6 by the method of Laemmli (1970) . Samples were heated at 100°C for 3 min in sample buffer with 1% 2-mercaptoethanol and then subjected to gel electrophoresis. Bovine serum albumin, ovalbumin, carbonic anhydrase, SBTI and lactalbumin (Sigma Chemical Co.) were used as protein standards. Protein was stained with 0.25% Coomassie Blue.
Determination of the N-terminus. The N-terminal amino acid residues of native and thermolysin-activated prokallikrein were determined by the dansylation technique (Gray, 1972; Hartley, 1970) . Purified prokallikrein (200 jug) was incubated with 100 ,tl (sedimented gel) of thermolysin-Sepharose in 0.1 M-Tris HCI buffer, pH 8.0, containing 10 mM-CaCl2 for 1 and 3 h at room temperature. After centrifugation at 12000 g for 2 min, the activity of the supernatant was measured with DVal-Leu-Arg-F3NMeC, and then applied to a column (0.75 cm x 30 cm) of TSK-G3000SW (Varian, Walnut Creek, CA, U.S.A.) in the h.p.l.c. system described above. Proteins were eluted with 0.07 M-sodium phosphate buffer, pH 7.2, containing 0.2 M-KCI at a flow rate of 0.3 ml/min. Essentially one protein peak was observed, which contained kallikrein activity. It was collected, dialysed against distilled water and then freeze-dried.
Native prokallikrein (200 ,ug) and prokallikrein (180 ,tg) activated by thermolysin-Sepharose were heated at 100°C for 2 min in 10% SDS and allowed to react with 25 mM-dansyl chloride in dimethylformamide for 2 h at room temperature. The dansylated protein was washed with acetone and then hydrolysed in 100 #1 of 6 M-HCl for 18 h at 105 'C. The hydrolysis products were identified by two-dimensional t.l.c. on a polyamide sheet (7.5 cm x 7.5 cm), dansyl-amino acids and dansyl-Ile-Val being used as standards. Three solvents were used for the chromatography: solvent 1, 1.5% (v/v) formic acid; solvent2,benzene/aceticacid,9: l,v/v; and solvent 3,ethyl acetate/methanol/acetic acid, 20: 1: 1, by vol.
Antibody preparation. Two New Zealand White rabbits were used for each immunization with active and pro-kallikrein. Purified prokallikrein (160,ug) or active kallikrein (180 ,g) was emulsified in an equal volume of complete Freund's adjuvant (1 ml total) and injected subcutaneously at 2-week intervals a total of three times. A booster injection with the same amount of antigen was administered 4 weeks later in incomplete Freund's adjuvant. Serum was collected 2 weeks after the final injection and heated at 56 'C for 30 min.
Immunodiffusion and immunoelectrophoresis. Double immunodiffusion was performed as described by Ouchterlony & Nilsson (1978) . Immunoelectrophoresis was done in 1.2% -(w/v)-agarose gel in 50 mM-Tris/glycine buffer, pH 8. 
Electrophoresis and immunodiffusion
The purified prokallikreirlmigrated as a single protein band in polyacrylamide-gel electrophoresis under denaturing and reducing conditions (Fig. 2) . A broad band was obtained with 25,g, but it was observed even when a smaller amount of the enzyme was subjected to SDS/polyacrylamide-gel electrophoresis, indicating microheterogeneity of prokallikrein, possibly because of variation in carbohydrate content. The apparent molecular mass was 48 kDa in either 9 % -or 12% -polyacrylamide gels in the presence of SDS.
Immunodiffusion experiments using antiserum to active kallikrein showed a single precipitin line against either active or pro-kallikrein, which fused completely (Fig. 3 a) . When antiserum to prokallikrein was placed in the centre well, precipitin lines formed with both active and pro-kallikrein. However, the prokallikrein precipitin line formed a spur and did not fuse completely with that of active kallikrein (Fig. 3b) (Fig. 4) To determine whether an autoactivation of prokallikrein would be possible, active human urinary kallikrein (11-109 nM) was tested as an activator, but it did not activate prokallikrein.
When purified kallikrein (2 ,ug) was incubated with thermolysin-or trypsin-Sepharose (100,1 of sedimented gel each) for 10-240 min at room temperature, the activity with D-Val-Leu-Arg-F3NMec substrate increased from 0.6 to about 27 nmol/min per ml within 10 min and stayed at this level during the remainder of the incubation. The maximal activation was equivalent to that obtained with 47 nM-free thermolysin or 215 nM-free trypsin.
Km values with native, purified active kallikrein, and thermolysin-or trypsin-Sepharose-activated prokallikrein were determined from Lineweaver-Burk plots at eight different concentrations ofD-Val-Leu-Arg-F3NMec substrate ranging from 4 to 40 /SM in 0.1 M-Tris/HCl buffer, pH 8.0. The Km values of the substrate with the three kallikreins were identical, 63 4aM, indicating that thermolysin and trypsin fully activated prokallikrein without further altering the catalytic site.
The apparent molecular mass of purified prokallikrein was 53 +2 kDa as determined by gel filtration on a Sephadex G-100 column. This value was higher than that obtained by SDS/polyacrylamide-gel electrophoresis (48000), possibly due to the glycoprotein nature of prokallikrein. The molecular masses of purified active kallikrein and thermolysin-or trypsin-Sepharose-treated prokallikrein were not significantly different from that of native prokallikrein (53 + 2 kDa) in gel filtration.
N-Terminal amino acid
To determine which peptide bond is cleaved by thermolysin in the prokallikrein molecule, the N-terminus ofprokallikrein before and after activation by thermolysin was examined. Alanine was the only N-terminal amino acid found with native prokallikrein, indicating homogeneity ofthe enzyme preparation. Isoleucine, Ile-Val and alanine were detected as the major spots and a faint valine spot was found after purified prokallikrein was activated with thermolysin-Sepharose for 1 h. After prolonged incubation for 3 h, the alanine spot could not be detected on-a-thinr-1ayer-plate, whereas the isoleucine and Ile-Val spots remained unchanged. This result indicates that thermolysin releases the N-terminal propeptide from prokallikrein and that the newly revealed N-terminal (Ile') of active kallikrein was linked to Val2, in agreement with the reported N-terminal sequence of active human urinary kallikrein (Lottspeich et al., 1979) . DISCUSSION We report here the first complete purification of human urinary prokallikrein and its activation by serine proteinases and a metalloproteinase. Because of the possibility that other serine proteinases may also cleave synthetic short substrates, both amidase and kininogenase activities of kallikrein were assayed during purification.
Urinary kallikrein originates from the kidney (Margolius, 1984; Scicli et al., 1978) . Its molecular mass, inhibition pattern and substrate specificity are similar to, or identical with, those of the glandular or tissue kallikrein, present in many organs (Fiedler, 1979) . The properties of this tissue kallikrein, however, are quite different from those of plasma kallikrein (Movat, 1979; Fig. 3) .
Extensive studies on urinary kallikrein were prompted by observations of decreased excretion of kallikrein in some forms of hypertension (Elliot & Nuzum, 1934; Margolius, 1980) and of the effects of kinins on prostaglandin release (Nasjletti & Malik, 1981 ; Abe et al., 1981) , sodium excretion and water reabsorption (Margolius, 1984) . Kinins filtered from blood by the glomerulus are inactivated in the brush border (Ward et al., 1975 (Ward et al., , 1976 Hall et al., 1976) . However, kinins are released by renal kallikrein, which enters the nephron in the distal tubule (Scicli et al., 1978) or the circulation from the basolateral membrane of the tubular cells (Yamada et al., 1981; Yamada & Erd6s, 1982; Nolly & Lama, 1981; Vio et al., 1981 Vio et al., , 1983 . Prokallikrein has been extracted from renal tissues (Nishimura & Erd6s, 1980; Nishimura et al., 1980a,b) and its release from kidney was noted (Nolly & Lama, 1981) . Nishimura et al. (1983) partially purified a rat renal prokallikrein after using proteolytic inhibitors, and Takaoka et al. (1982) separated rat urinary prokallikrein from active kallikrein by ion-exchange chromatography.
Our purification, consisting of six steps, separated active and pro-kallikrein completely. The purified human urinary proenzyme appeared to be homogeneous. As observed with human urinary kallikrein, variation in carbohydrate content may cause a microheterogeneity in polyacrylamide-gel electrophoresis (Ikekita et al., 1983; Morichi et al., 1984) . Antisera to active kallikrein did cross-react with prokallikrein and vice versa. However, antisera to prokallikrein contained antibodies to determinants (presumably of the propeptide) not found on active kallikrein.
Purified prokallikrein, active kallikrein and thermolysin-or trypsin-Sepharose-activated prokallikrein had similarmolecularmassesin gel filtration (53 + 2 kDa). This was not unexpected, because in rat prokallikrein (Swift et al., 1982) , the activation peptide contains only 11 amino acids. Thus, if activation of human prokallikrein only changes the molecular mass by about 1 kDa, this would not be detected in gel filtration.
The N-terminal amino acid of prokallikrein is alanine as determined by the dansylation technique, but the N-terminal end could have been modified by aminopeptidases during processing in the kidney or after excretion into the urine. After activation by thermolysin, Dns-Ile, Dns-Ile-Val and Dns-Ala were found, in good agreement with the reported Ile'-Val2 at the N-terminus of active human urinary kallikrein (Lottspeich et al., 1979) . The trace amount ofDns-Ala found came from the N-terminal end of the remaining proenzyme, because it disappeared after prolonged incubation with thermolysin-Sepharose. The release of the N-terminal Ile-Val was expected, as this bond is resistant to acid hydrolysis (Gray, 1972) . These data indicate that thermolysin cleaved the bond between the activation peptide and kallikrein in the prokallikrein molecule.
Thermolysin, after activating prokallikrein, did not cleave the released active kallikrein any further. When chymotrypsinogen is activated, its newly formed Nterminal end (Ile) is protected against further degradation by folding down into the molecule, where it forms an ionic bond with Asp-194 (Kraut, 1971) . A similar mechanism may be involved in the activation of glandular kallikrein.
Prokallikrein was activated by serine proteinases as well. It is known that trypsin (Werle & Urhahn, 1940; Werle, 1960; Werle & Vogel, 1960 , 1961 Corthorn et al., 1979; Spragg, 1983) , plasmin or pronase (Noda et al., 1985) can activate human renal (Nishimura & Erdos, 1980) and urinary prokallikrein. Crude prokallikrein preparations may contain protein inhibitors (Kraut et al., 1930; Vogel, 1979) ; thus an apparent increase in activity could be due to the destruction of an inhibitor as well as to the activation of the proenzyme.
In addition to the enzymes mentioned, human plasma kallikrein activates homogeneous urinary prokallikrein to the same extent as the other enzymes, although at higher concentrations. Trypsin-like serine proteinases cleave peptides and proteins at the carboxy end of basic amino acids. The nucleotide sequence of rat pancreatic preprokallikrein (Swift et al., 1982) indicates that the propeptide is linked to active kallikrein through an Arg-1-Val+1 bond. Arginine is also the C-terminal amino acid of the activation peptide in prorenin (Imai et al., 1983) , which also can be activated, at least in vitro, by trypsin, kallikrein and plasmin (Sealey & Atlas, 1984; Schalekamp & Derkx, 1981) . The same type of basic-to-hydrophobic-amino-acid link was also found. for example, in the precursors of trypsin (MacDonald et al., 1982a) , epidermal-growth-factor-binding protein (Lundgren et al., 1984) , parathyroid hormone (Habener et al., 1984) , chymotrypsinogen and proelastase (MacDonald et al., 1982b) . Very likely the activation or propeptide sequence of human renal prokallikrein is linked to the active enzyme through an Arg-1-Ile+1 bond, since isoleucine is the N-terminal amino acid of purified tissue kallikrein, followed by Val2 (Lottspeich et al., 1979) .
Because renal prokallikrein extracted from particulate fractions was activated by thermolysin, an enzyme which cleaves at the N-terminal end of hydrophobic amino acids (Noda et al., 1985; Matsubara & Feder, 1971) , we tested thermolysin as a prototype enzyme for activation of homogeneous prokallikrein by a neutral metalloproteinase. Indeed, on a molar basis, thermolysin was three times more effective than trypsin in liberating active human renal kallikrein. A catalytic amount of thermolysin (1: 50 molar ratio with prokallikrein) activated 50 % in 30 min. As added active human urinary kallikrein was inactive, it is unlikely that activation of prokallikrein would involve a cascade where the release of a trace of active urinary kallikrein autoactivates prokallikrein.
Thermolysin (Matsubara & Feder, 1971 ) was purified from bacteria, but an enzyme that cleaves similar substrates in vitro and is inhibited by the same inhibitors has been purified from mammalian tissues (Kerr & Kenny, 1974; Schwartz et al., 1981; Matsas et al., 1983; Relton et al., 1983) , including the human kidney (Gafford et al., 1983) . This enzyme, endopeptidase-24. 11, however, appears to have a more restricted active site, because the B-chain of insulin is among its higher-molecular-mass substrates; thus it may not cleave proteins. However, various mammalian cells contain other metalloproteinases, although they are not as well characterized as the endopeptidase-24. 11. These enzymes resemble thermolysin and appear to be involved in important functions. These include neuromuscular transmission (Baxter et al., 1983) , myoblast fusion (Couch & Strittmatter, 1984) and mast-cell exocytosis (Mundy & Strittmatter, 1985) . Their role in the activation of proenzymes needs to be determined.
It is of interest that plasma kallikrein activates urinary prokallikrein. Glandular kallikrein (and possibly prokallikrein as well) released from salivary gland (Rabito et al., 1982 or from the basolateral membrane of the distal tubules of the kidney (Yamada et al., 1981; Figueroa et al., 1983) appears in circulating blood. Free kinins in plasma may be released from the low-molecularmass kininogen by glandular-tissue kallikrein . Thus, conditions which lead to activation of Vol. 232 plasma prokallikrein (Kaplan et al., 1983) , such as blood clotting or thrombus formation in tissues, may result in the activation of a tissue prokallikrein as a consequence.
